IBRUTINIB 依鲁替尼 A Btk protein inhibitor.


Ibrutinib.svg
IBRUTINIB 依鲁替尼

A Btk protein inhibitor.

1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one

CAS NUMBER 936563-96-1
Ibrutinib, PCI 32765, PCI32765, ibrutinibum, IMBRUVICA,
CRA-032765
Ibrutinib
Imbruvica
Pc-32765
PCI 32765
PCI32765
UNII-1X70OSD4VX
Molecular Formula: C25H24N6O2
Molecular Weight: 440.49706
Company: Pharmacyclics
Approval Status: Approved February 2014US FDA:link
Treatment Area: chronic lymphocytic leukemia

Bruton’s tyrosine kinase (Btk) inhibitor

U.S. Patent No: 7,514,444 , 7,718,662
patent validity: December 2026

http://newdrugapprovals.org/2014/02/27/ibrutinib-%E4%BE%9D%E9%B2%81%E6%9B%BF%E5%B0%BC/

Topic : Health
Genre : Mental/Health

Post a comment

Private comment

Comment is pending approval.

Comment is pending administrator's approval.